Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31361235 | 0.74 | NPC1 (0.38) | NPC1RAB9A | |
| SCHEMBL24416958 | 0.73 | CYP11B1 (0.35) | CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL6981757 | 0.72 | CTSK (0.44) | SOS2CTSK | |
| SCHEMBL29713462 | 0.68 | KDM4E (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL24416920 | 0.68 | CYP11B1 (0.42) | CYP11B1CYP11B2NPC1 | |
| SCHEMBL21873113 | 0.68 | KDM4E (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL28031858 | 0.68 | EGLN2 (0.39) | CYP11B1CYP11B2SOS2 | |
| SCHEMBL24417213 | 0.67 | CYP11B1 (0.30) | CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL24417419 | 0.67 | RAB9A (0.35) | CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL23106711 | 0.66 | KDM4E (0.41) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20140045802-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045802-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| EP-2234985-B1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2010078953-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2009135599-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045802-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | CYP11B1 18/4885CYP11B2 8/4885SOS2 3197/4885 |
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | QDPR, DPYD, DPP4 | CYP11B1 101/4885CYP11B2 27/4885SOS2 1919/4885 |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | TNNI3, TNNT2, PC | CYP11B1 19/4885CYP11B2 4/4885SOS2 2940/4885 |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | CYP11B1 347/4885CYP11B2 242/4885SOS2 2524/4885 |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | CYP11B1 18/4885CYP11B2 8/4885SOS2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.